biostudies-literatureEvans DGNCI NIH HHSNational Breast Cancer Foundation1524-1532https://www.ebi.ac.uk/biostudies/studies/S-EPMC8076275biostudies-literatureUnknown124(9)<h4>Background</h4>The impact of various breast-cancer treatments on patients with a BRCA2 mutation has not been studied. We sought to estimate the impact of bilateral oophorectomy and other treatments on breast cancer-specific survival among patients with a germline BRCA2 mutation.<h4>Methods</h4>We identified 664 women with stage I-III breast cancer and a BRCA2 mutation by combining five different datasets (retrospective and prospective). Subjects were followed for 7.2 years from diagnosis to death from breast cancer. Tumour characteristics and cancer treatments were patient-reported and derived from medical records. Predictors of survival were determined using Cox proportional hazard models, adjusted for other treatments and for prognostic features.<h4>Results</h4>The 10-year breast-canBritish journal of cancerSurvival from breast cancer in women with a BRCA2 mutation by treatment.PMC8076275IF-17-002PRAC-17-004R01 CA159868Wasko BkConFab Investigators, Polish Hereditary Breast Cancer Consortium, Hereditary Breast Cancer Clinical Study GroupEisen AChosia MEkholm MKordek RO'Connor SLubinski JStanhope LUrbanski KSweet KPhillips KAHyder ZGozdz SBlasinska-Morawiec MMierzwa TPicken SSun PJeziorski AMorawiec ZEvans DGGronwald JMitus JWNesci SDrosik KEng CNeuhausen SMcKinnon WMilne RLMoller PMcLachlan SARys JLamperska KMackiewicz AZakalik DGugala KTung NAinsworth PGozdecka-Grodecka SSzczylik CSinger CNiepsuj SWeitzel JSenter LCullinane CKozak-Klonowska BSynowiec AForde CPosmyk MFoulkes WKarlan BLange DFruscio RHuzarski TNarod SAOszurek OMetcalfe KFriedlander MKim RUcinski MGrzybowska EWandzel PCybulski CCouch FKarczewska AWood MfalseSurvival from breast cancer in women with a BRCA2 mutation by treatment.<h4>Background</h4>The impact of various breast-cancer treatments on patients with a BRCA2 mutation has not been studied. We sought to estimate the impact of bilateral oophorectomy and other treatments on breast cancer-specific survival among patients with a germline BRCA2 mutation.<h4>Methods</h4>We identified 664 women with stage I-III breast cancer and a BRCA2 mutation by combining five different datasets (retrospective and prospective). Subjects were followed for 7.2 years from diagnosis to death from breast cancer. Tumour characteristics and cancer treatments were patient-reported and derived from medical records. Predictors of survival were determined using Cox proportional hazard models, adjusted for other treatments and for prognostic features.<h4>Results</h4>The 10-year breast-can2021-01-01T00:00:00Z2021 Apr2025-04-03T21:30:01.242Z2025-04-03T21:30:01.242ZS-EPMC80762753359771610.1038/s41416-020-01164-1